Is Wegovy the Same as Ozempic? Is Zepbound the Same as Mounjaro? Complete GLP-1 Disambiguation FAQ (2026)

This disambiguation FAQ is part of Weight Loss Rankings' living editorial database — 100+ research articles and 158+ clinically-reviewed GLP-1 telehealth providers, sourced only from primary FDA labels (DailyMed) and peer-reviewed PubMed literature.

The questions patients actually ask Google are not always intuitive. GLP-1 is a drug class — not a specific drug. Wegovy and Ozempic share an active ingredient (semaglutide) but are different brands at different maximum doses for different FDA-approved indications. Zepbound and Mounjaro are the same molecule (tirzepatide) — but tirzepatide is a dual GIP/GLP-1 receptor agonist, not a pure GLP-1, per the verbatim §12.1 mechanism-of-action language in the FDA-approved DailyMed labels [4, 5]. Wegovy and Mounjaro are different molecules entirely. This article works through 21 of the most- searched same-as / vs / class-membership questions with verbatim YES/NO answers anchored to DailyMed [1, 2, 3, 4, 5, 6, 7].

About this article

The two simplest rules

Most disambiguation questions resolve to one of two rules:

1. Same molecule → different brand for different indication. Wegovy and Ozempic are both semaglutide; Zepbound and Mounjaro are both tirzepatide; Saxenda and Victoza are both liraglutide. The brand split exists because the FDA approves drugs by indication, and a higher-dose obesity-indicated brand needs a separate regulatory filing from the diabetes-indicated brand.
2. Different molecule → different drug entirely. Wegovy (semaglutide) is not Mounjaro (tirzepatide). Ozempic (semaglutide) is not Trulicity (dulaglutide). Foundayo (orforglipron) is not Rybelsus (oral semaglutide). Different molecules have different efficacy, different side-effect profiles, different dosing schedules, and different manufacturers.

Almost every is X the same as Y question can be answered by identifying which active ingredient is in each brand and applying these two rules.

Wegovy vs Ozempic vs Saxenda (semaglutide and liraglutide brand families)

Three Novo Nordisk brand families dominate this confusion:

• Semaglutide injectables: Wegovy (2.4 mg once weekly, FDA-approved for chronic weight management) and Ozempic (up to 2.0 mg once weekly, FDA-approved for type 2 diabetes). Same molecule, different brands, different maximum doses, different indications [1, 2].
• Semaglutide oral: Rybelsus (3, 7, or 14 mg once daily, FDA-approved for type 2 diabetes only). Same molecule as Wegovy and Ozempic, different formulation (tablet with SNAC absorption enhancer), narrower indication [6].
• Liraglutide injectables: Saxenda (3 mg/day, FDA-approved for chronic weight management) and Victoza (up to 1.8 mg/day, FDA-approved for type 2 diabetes). Same molecule, different brands, different maximum doses, different indications [3]. Generic liraglutide exists for both indications as of 2024-2025.

For the full comparison table — efficacy, dosing, mechanism, and channel — see the dedicated brand-name cheat sheet.

Mounjaro vs Zepbound (the tirzepatide brand family)

Eli Lilly markets tirzepatide under two brand names:

• Mounjaro — FDA-approved May 2022 for type 2 diabetes. Maximum dose 15 mg once weekly [5].
• Zepbound — FDA-approved November 2023 for chronic weight management; expanded December 2024 to include moderate-to-severe obstructive sleep apnea in adults with obesity. Maximum dose 15 mg once weekly [4].

The active ingredient, dose strengths, titration schedule, injection device, and safety profile are identical between the two brands. The clinical experience for a patient is the same — only the indication, the package, and (often) the insurance coverage rules differ.

For the full comparison, see Mounjaro vs Zepbound: complete comparison.

Why these brands have multiple versions

The pattern of same molecule, different brand for different indication is older than GLP-1s. Bupropion is sold as Wellbutrin (depression) and Zyban (smoking cessation). Finasteride is sold as Proscar (BPH, 5 mg) and Propecia (male- pattern baldness, 1 mg). Sildenafil is sold as Viagra (ED) and Revatio (pulmonary arterial hypertension).

The pattern reflects three things. First, the FDA reviews and approves drugs by indication, so a manufacturer seeking a new indication for an existing molecule files a separate application with separate trials. Second, dose differences between indications often justify a separate package and label (Saxenda 3 mg/day vs Victoza 1.8 mg/day, Wegovy 2.4 mg vs Ozempic 2.0 mg). Third, payer coverage and prescribing patterns differ across indications, and a separate brand makes it easier for prescribers, pharmacists, and payers to track utilization to the correct indication.

Drug-class confusion: GLP-1 vs Ozempic

GLP-1 is the name of a drug class. It is short for “glucagon-like peptide-1 receptor agonist” — a category of medications that bind to and activate the GLP-1 receptor. Many drugs are in this class, including:

• Semaglutide (Wegovy, Ozempic, Rybelsus — Novo Nordisk)
• Liraglutide (Saxenda, Victoza, Hikma generic, Teva generic)
• Dulaglutide (Trulicity — Eli Lilly, Fc-fusion biologic)
• Exenatide (Byetta and Bydureon BCise — discontinued by AstraZeneca October 2024; Amneal generic exenatide approved November 2024)
• Orforglipron (Foundayo — Eli Lilly, oral non-peptide)

Ozempic is one specific drug (semaglutide injection for type 2 diabetes) within this class. Saying “I'm on a GLP-1” tells you the class but not the specific drug. Saying “I'm on Ozempic” tells you the specific drug — and identifies the molecule (semaglutide), manufacturer (Novo Nordisk), indication (type 2 diabetes), and dose range (up to 2.0 mg once weekly).

Tirzepatide is a dual agonist, not a GLP-1 alone

This is the single most important YMYL nuance in the article. Tirzepatide — the active ingredient in Mounjaro and Zepbound — is described in §12.1 of the FDA-approved DailyMed labels as “a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist” [4, 5]. It activates both the GIP and GLP-1 receptors.

That distinction matters because:

• The mechanism is genuinely different. GIP activation contributes additively to weight loss and glycemic control on top of GLP-1 activation, which is one reason tirzepatide produces greater weight loss than semaglutide head-to-head (SURMOUNT-5, NEJM 2025).
• Class-effect language can mislead. A claim like “all GLP-1s cause X side effect” may apply differently to tirzepatide because of the GIP contribution. Side-effect rates from tirzepatide trials should not be directly extrapolated from semaglutide trials and vice versa.
• Some emerging investigational drugs add a third receptor. Retatrutide (Eli Lilly investigational) is a triple agonist of GIP, GLP-1, and glucagon receptors — a different class again. The pipeline is increasingly multi-receptor.

In casual conversation, grouping tirzepatide with the GLP-1s is acceptable shorthand. In a clinical or YMYL context — drug comparisons, side-effect attribution, mechanism explanations — the dual-agonist classification is the correct one and the FDA label uses it explicitly.

All 21 questions answered

1. Is Wegovy the same as Ozempic?

YES — same active ingredient, different brand. Wegovy and Ozempic both contain semaglutide and are both made by Novo Nordisk. They differ in:

• FDA-approved indication: Wegovy for chronic weight management; Ozempic for type 2 diabetes.
• Maximum dose: Wegovy 2.4 mg once weekly; Ozempic up to 2.0 mg once weekly.
• Pen format: Wegovy single-dose pre-filled pens; Ozempic multi-dose pens [1, 2].

2. Is Zepbound the same as Mounjaro?

YES — same active ingredient, different brand. Both contain tirzepatide and are made by Eli Lilly. They share the same dose strengths (2.5, 5, 7.5, 10, 12.5, 15 mg), the same once-weekly schedule, and the same titration. They differ in indication: Zepbound for chronic weight management plus obstructive sleep apnea in adults with obesity; Mounjaro for type 2 diabetes [4, 5].

3. Is Saxenda the same as Victoza?

YES — same active ingredient, different brand and dose. Both contain liraglutide and are made by Novo Nordisk. Saxenda titrates to 3 mg/day for chronic weight management; Victoza titrates to a maximum of 1.8 mg/day for type 2 diabetes [3]. Generic liraglutide is now FDA-approved for both indications (Hikma 2024 referencing Victoza, Teva 2025 referencing Saxenda).

4. Is Rybelsus the same as Ozempic?

Same active ingredient, different formulation. Both contain semaglutide and are made by Novo Nordisk. Rybelsus is an oral tablet using the SNAC absorption enhancer to allow gastrointestinal absorption of the peptide. Ozempic is a subcutaneous injection. Both are FDA-approved for type 2 diabetes only — neither is approved for chronic weight management [2, 6].

5. Is Mounjaro a semaglutide?

NO. Mounjaro is tirzepatide, made by Eli Lilly. Tirzepatide is a dual GIP/GLP-1 receptor agonist, chemically and mechanistically different from semaglutide [5]. Patients sometimes confuse the two because both are once-weekly injectable peptides FDA-approved for type 2 diabetes — but they are different drugs from different manufacturers.

6. Is Zepbound a semaglutide?

NO. Zepbound is tirzepatide, made by Eli Lilly — the same molecule as Mounjaro. Wegovy is the semaglutide-based product approved for chronic weight management; Zepbound is the tirzepatide-based product approved for chronic weight management. They are different molecules with different mechanisms [1, 4].

7. Is Wegovy a tirzepatide?

NO. Wegovy is semaglutide 2.4 mg, made by Novo Nordisk. It is a pure GLP-1 receptor agonist [1]. Tirzepatide is the active ingredient in Mounjaro and Zepbound from Eli Lilly. Patients searching for “tirzepatide Wegovy” or “Wegovy tirzepatide” are conflating two different brands from two different manufacturers.

8. Is Foundayo the same as Rybelsus?

NO. Foundayo is orforglipron, a non-peptide small-molecule GLP-1 receptor agonist made by Eli Lilly, FDA-approved on April 1, 2026 for chronic weight management. Rybelsus is oral semaglutide — a peptide formulated with the SNAC absorption enhancer — made by Novo Nordisk and approved for type 2 diabetes only [6]. Different molecules, different chemistry classes (small-molecule vs peptide), different indications, different food restrictions, different manufacturers.

9. Is Trulicity the same as Ozempic?

NO. Trulicity contains dulaglutide — a long-acting GLP-1 receptor agonist Fc-fusion biologic consisting of two GLP-1 analog peptides covalently linked to an Fc fragment of human IgG4 [7]. Ozempic contains semaglutide, a synthetic peptide [2]. Both are once-weekly subcutaneous injections approved for type 2 diabetes only, but they are structurally and chemically different molecules from different manufacturers (Eli Lilly vs Novo Nordisk).

10. Is Wegovy a GLP-1?

YES. Wegovy contains semaglutide, a GLP-1 receptor agonist. The Wegovy DailyMed §12.1 mechanism of action describes semaglutide as a glucagon-like peptide-1 (GLP-1) analog [1]. It is one of the prototypical drugs in the GLP-1 class.

11. Is Mounjaro a GLP-1?

Partially. Tirzepatide — the active ingredient in Mounjaro and Zepbound — is described in §12.1 of both DailyMed labels as “a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist” [4, 5]. It activates both receptors. In casual conversation it is often grouped with the GLP-1s; in clinical and FDA-label terms it is a dual incretin agonist — a related but distinct class.

This nuance matters when extrapolating side-effect rates, head-to-head efficacy, or mechanism-based reasoning. See the section above on “Tirzepatide is a dual agonist” for why this is the most important YMYL distinction in the article.

12. Is Foundayo a GLP-1?

YES. Foundayo contains orforglipron, a non-peptide small-molecule GLP-1 receptor agonist. Unlike peptide GLP-1s (semaglutide, liraglutide), orforglipron is a small molecule that binds the GLP-1 receptor through an allosteric site. The mechanism class — GLP-1 receptor agonism — is the same; the chemistry (small-molecule vs peptide) is different.

13. Is Trulicity a GLP-1?

YES. Trulicity contains dulaglutide, a long-acting GLP-1 receptor agonist consisting of two GLP-1 analog peptides covalently linked to an Fc fragment of human IgG4 [7]. It is a biologic GLP-1 receptor agonist, and the DailyMed §12.1 mechanism of action describes it as such.

14. Is GLP-1 the same as Ozempic?

NO. GLP-1 is a drug class — the category of medications that activate the glucagon-like peptide-1 receptor. Ozempic is one specific drug (semaglutide injection for type 2 diabetes) within that class. Saying “GLP-1” in conversation does not specify which drug; saying “Ozempic” identifies a single molecule, brand, manufacturer, indication, and dose range.

15. Is semaglutide a GLP-1?

YES. Semaglutide is a synthetic peptide GLP-1 receptor agonist. It is the active ingredient in Wegovy (weight management injectable), Ozempic (type 2 diabetes injectable), and Rybelsus (type 2 diabetes oral tablet) — all made by Novo Nordisk [1, 2, 6].

16. Is GLP-1 the same as semaglutide?

NO. GLP-1 is the broader drug class. Semaglutide is one specific molecule within that class. Liraglutide, dulaglutide, exenatide, orforglipron, and (with the dual-mechanism caveat) tirzepatide are also in or adjacent to the GLP-1 class. Saying “GLP-1” can refer to any of them; saying “semaglutide” refers to a single molecule.

17. Is Wegovy the same as Saxenda?

NO. Both are FDA-approved for chronic weight management and both are made by Novo Nordisk, but the active ingredients differ. Wegovy is semaglutide 2.4 mg once weekly; Saxenda is liraglutide 3 mg once daily. Semaglutide is the longer-acting and more potent of the two — STEP-1 reported ~14.9% weight loss at 68 weeks vs ~5-6% historically for liraglutide 3 mg over 56 weeks.

18. Is Wegovy the same as Mounjaro?

NO. Wegovy is semaglutide 2.4 mg (Novo Nordisk), FDA-approved for chronic weight management. Mounjaro is tirzepatide up to 15 mg (Eli Lilly), FDA-approved for type 2 diabetes only. Different molecules (GLP-1 only vs dual GIP/GLP-1), different mechanisms, different manufacturers, different indications [1, 5].

For the side-by-side decision guide, see Wegovy vs Mounjaro: different molecules, different indications.

19. Is Zepbound the same as Wegovy?

NO. Both are FDA-approved for chronic weight management — but they are different molecules. Zepbound is tirzepatide (Eli Lilly, dual GIP/GLP-1 receptor agonist). Wegovy is semaglutide (Novo Nordisk, GLP-1 receptor agonist). SURMOUNT-5 (NEJM 2025) compared the two head-to-head in chronic weight management; tirzepatide produced greater mean weight loss [1, 4].

20. Is generic semaglutide the same as Ozempic or Wegovy?

No FDA-approved generic semaglutide exists in the United States as of May 2026. Ozempic, Wegovy, and Rybelsus remain branded products under Novo Nordisk's active patent. Patients sometimes refer to compounded semaglutide as a “generic” — this is incorrect. Compounded semaglutide produced by 503A and 503B compounding pharmacies is not an FDA-approved generic; it is a pharmacy- compounded preparation, regulated differently under FDCA §503A and §503B. The FDA has explicitly stated that compounded semaglutide does not have the FDA-approved generic designation.

21. Is generic liraglutide the same as Saxenda or Victoza?

YES — FDA-approved generic liraglutide exists. Hikma received FDA approval in December 2024 for the first generic liraglutide referencing Victoza (type 2 diabetes indication) — the first FDA-approved generic GLP-1 receptor agonist of any kind. Teva received FDA approval on August 28, 2025 for the first generic liraglutide 3 mg referencing Saxenda (chronic weight management indication) — the first FDA-approved generic GLP-1 receptor agonist for chronic weight management. As FDA-approved generics, both products are bioequivalent to their reference brands.

Quick-reference disambiguation table

Bottom line

• GLP-1 is a drug class. Ozempic is one specific drug in that class. The two are not interchangeable terms.
• Wegovy and Ozempic are the same active ingredient (semaglutide, Novo Nordisk) at different maximum doses for different FDA-approved indications [1, 2].
• Zepbound and Mounjaro are the same active ingredient (tirzepatide, Eli Lilly) at the same maximum dose for different FDA-approved indications [4, 5].
• Saxenda and Victoza are the same active ingredient (liraglutide, Novo Nordisk) at different maximum doses for different FDA-approved indications [3]. Generic liraglutide is now FDA-approved for both indications.
• Tirzepatide is a dual GIP/GLP-1 receptor agonist — per the verbatim §12.1 of the Mounjaro and Zepbound DailyMed labels — not a pure GLP-1 [4, 5]. This is the single most important YMYL nuance in the article.
• No FDA-approved generic semaglutide exists in the United States as of May 2026. Compounded semaglutide is not an FDA-approved generic.
• FDA-approved generic liraglutide exists for both type 2 diabetes (Hikma, Dec 2024) and chronic weight management (Teva, Aug 2025).

Important disclaimer

This article is educational and reports verified brand-to-active-ingredient and brand-to-indication mappings from the FDA-approved DailyMed prescribing information for each product. None of this constitutes medical advice. Indication, dose, brand selection, and switching decisions are clinical decisions made between a patient and their prescriber. Weight Loss Rankings does not provide medical advice, diagnosis, or treatment recommendations.

Related research

For the side-by-side comparison of all four headline brands, see the Wegovy vs Ozempic vs Zepbound vs Mounjaro brand-name cheat sheet. For the indication-vs-formulation framing in more depth, see diabetes vs weight-loss GLP-1 disambiguation. For the same-molecule, different-brand comparison of the tirzepatide family, see Mounjaro vs Zepbound: complete comparison. For the cross-molecule decision between the two leading chronic-weight-management options, see Wegovy vs Mounjaro: different molecules, different indications. For the full reference list of every FDA-approved GLP-1, see the GLP-1 medication list 2026. For the oral GLP-1 family (Rybelsus, Foundayo), see GLP-1 pills 2026: Rybelsus vs Foundayo vs oral semaglutide. For the broader GLP-1 overview, see the GLP-1 complete guide.